Literature DB >> 14739366

Tie2-Cre-induced inactivation of a conditional mutant Nf1 allele in mouse results in a myeloproliferative disorder that models juvenile myelomonocytic leukemia.

Aaron D Gitler1, Yi Kong, John K Choi, Yuan Zhu, Warren S Pear, Jonathan A Epstein.   

Abstract

Neurofibromatosis type one (NF1) is a common genetic disorder affecting 1:4000 births and is characterized by benign and malignant tumors. Children with NF1 are predisposed to juvenile myelomonocytic leukemia. The Nf1 gene encodes neurofibromin, which can function as a Ras GTPase-activating protein. Neurofibromin deficiency in mice leads to mid-gestation lethality due to cardiovascular defects. We have previously shown that conditional inactivation of Nf1 using Tie2-Cre recapitulates the heart defects seen in Nf1(-/-) embryos. Tie2-Cre transgenic mice express Cre recombinase in all endothelial cells. Here, we show that Tie2-Cre-mediated deletion of Nf1 also leads to excision of Nf1 in the hematopoietic lineage. Surviving mice exhibit a myeloproliferative disorder similar to juvenile myelomonocytic leukemia seen in NF1 patients. These mice provide a useful model to study neurofibromin deficiency in hematopoiesis. Furthermore, defects in Tie2-Cre-expressing progenitors that result in heart and blood defects suggest that related heart and blood disorders in NF1 and other syndromes represent disorders of the hemangioblast.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14739366     DOI: 10.1203/01.PDR.0000113462.98851.2E

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  21 in total

Review 1.  The molecular mechanisms that control thrombopoiesis.

Authors:  Kenneth Kaushansky
Journal:  J Clin Invest       Date:  2005-12       Impact factor: 14.808

2.  FoxO4 promotes early inflammatory response upon myocardial infarction via endothelial Arg1.

Authors:  Min Zhu; Sean C Goetsch; Zhaoning Wang; Robert Luo; Joseph A Hill; Jay Schneider; Sidney M Morris; Zhi-Ping Liu
Journal:  Circ Res       Date:  2015-10-05       Impact factor: 17.367

Review 3.  Hematopoietic growth factors, signaling and the chronic myeloproliferative disorders.

Authors:  Kenneth Kaushansky
Journal:  Cytokine Growth Factor Rev       Date:  2006-10-20       Impact factor: 7.638

4.  Tie2Cre-mediated inactivation of plexinD1 results in congenital heart, vascular and skeletal defects.

Authors:  Ying Zhang; Manvendra K Singh; Karl R Degenhardt; Min Min Lu; Jean Bennett; Yutaka Yoshida; Jonathan A Epstein
Journal:  Dev Biol       Date:  2008-10-17       Impact factor: 3.582

Review 5.  Ras oncogenes: split personalities.

Authors:  Antoine E Karnoub; Robert A Weinberg
Journal:  Nat Rev Mol Cell Biol       Date:  2008-07       Impact factor: 94.444

6.  Cardiac and vascular functions of the zebrafish orthologues of the type I neurofibromatosis gene NFI.

Authors:  Arun Padmanabhan; Jeong-Soo Lee; Fraz A Ismat; Min Min Lu; Nathan D Lawson; John P Kanki; A Thomas Look; Jonathan A Epstein
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-04       Impact factor: 11.205

Review 7.  Nonredundant functions for Ras GTPase-activating proteins in tissue homeostasis.

Authors:  Philip D King; Beth A Lubeck; Philip E Lapinski
Journal:  Sci Signal       Date:  2013-02-26       Impact factor: 8.192

Review 8.  Modeling cognitive dysfunction in neurofibromatosis-1.

Authors:  Kelly A Diggs-Andrews; David H Gutmann
Journal:  Trends Neurosci       Date:  2013-01-08       Impact factor: 13.837

9.  Germ line activation of the Tie2 and SMMHC promoters causes noncell-specific deletion of floxed alleles.

Authors:  Willem J de Lange; Carmen M Halabi; Andreas M Beyer; Curt D Sigmund
Journal:  Physiol Genomics       Date:  2008-07-08       Impact factor: 3.107

10.  Molecular signatures of quiescent, mobilized and leukemia-initiating hematopoietic stem cells.

Authors:  E Camilla Forsberg; Emmanuelle Passegué; Susan S Prohaska; Amy J Wagers; Martina Koeva; Joshua M Stuart; Irving L Weissman
Journal:  PLoS One       Date:  2010-01-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.